key: cord-0916054-ze4v4q5o
authors: Engelstad, Kristin; Salazar, Rachel; Koenigsberger, Dorcas; Stackowtiz, Erin; Brodlie, Susan; Brandabur, Melanie; De Vivo, Darryl C.
title: Exploring triheptanoin as treatment for short chain enoyl CoA hydratase deficiency
date: 2021-05-01
journal: Ann Clin Transl Neurol
DOI: 10.1002/acn3.51359
sha: b718cf6e4406f4deb2ee19bb0aa87658128843da
doc_id: 916054
cord_uid: ze4v4q5o

We explored the benefits of triheptanoin as a treatment for Short Chain Enoyl Co‐A Hydratase (SCEH) deficiency. One child with early onset, severe SCEH Deficiency was treated with triheptanoin, an odd chain oil with anapleurotic properties, for 37 months. Blood and urine chemistry safety measures, motor skills assessment, physical exam, and neurological assessment were monitored over a 27 month period. Modest sustained gains in motor skills, attention, muscle bulk, and strength were observed without any significant adverse effects. Triheptanoin appears to be a promising effective treatment for SCEH Deficiency.

Short Chain Enoyl Co-A Hydratase (SCEH) deficiency is a phenotypically heterogeneous disorder ranging from an early onset severe progressive Leigh-Like Syndrome with early demise 1,2 to later onset childhood movement disorders. 3, 4 Early onset symptoms include hypotonia, respiratory insufficiency, global developmental delay, encephalopathy, sensorineural hearing loss, cardiomyopathy, and bilateral basal ganglia lesions. 5 Less common are the later onset mildly symptomatic patients with varied movement disorders and basal ganglia lesions. [4] [5] [6] Intermediate phenotypes also have been reported. 5, 7 Median life expectancy is approximately 2 years. 8 Last reported age of 24 early onset patients, alive at time of the report, was 104.8 + 95 months (range 8-372 months). Lactate values (blood, CSF, and brain magnetic resonance spectroscopy) in severe cases are elevated, and pyruvate values may be elevated or normal. 5 In contrast, intermediate and mild cases usually have normal laboratory values. A review of the literature 1-4,6-29 revealed 67 patients with most suffering the early onset presentation. Average age at death was 28.0 + 43.8 months (range 16 h to 156 months) for 27 early onset patients (age <12 months) for whom age at death was reported. SCEH deficiency is caused by bi-allelic mutations in the ECHS1 gene which encodes short chain enoyl CoA hydratase. Mutation types vary with the missense variant being the most common. 23 SCEH is a mitochondrial matrix enzyme that catalyzes the second step of fatty acid beta-oxidation converting medium and short chain 2-enoylacyl-CoA to 3-hydroxyacyl-CoA 10, 11, 18 (Figure 1 ), Fatty acid oxidation intermediates are generally normal with some reports of elevated C4 acylcarnitine. 18 SCEH is also involved in valine metabolism; converting methacrylyl-CoA to 3-hydoxybutyryl and acryloyl-CoA to 3-hydroxypropionyl-CoA. 10 Both methacrylyl-CoA and acryloyl-CoA are elevated in patients with SCEH deficiency. 10, 30 Elevated levels of erythro-2,3 dihydroxy-2-methylbutyrate, 7,21 3-methylgluconate, lactate, methylacryloyl-CoA, and acryloyl-CoA 21 also have been reported.

Methacrylyl-CoA and acryloyl-CoA toxicity is thought to be the cause of the brain pathology 21 impairing the pyruvate dehydrogenase complex and the electron transport chain. 18, 30 Pyruvate dehydrogenase deficiency has been reported in the early onset patients but not uniformly. 30 Sakai et al reported an early onset child, with reductions in respiratory chain complexes, I, III, and IV, but this disturbance has not been found in all patients. SCEH is also involved with isoleucine and leucine metabolism; however, these metabolites have not been disturbed in patients with SCEH Deficiency, so it is assumed that SCEH does not play a significant role in these pathways. 30 There is no cure for SCEH Deficiency, but various symptomatic treatments have been attempted. The ketogenic diet has generally not been helpful, although there is one mild patient whose dystonia improved. 4 Vitamin cocktails are not useful. Dystonia in one mild patient improved on a low protein diet. 4 Another mild patient was given carnitine, creatine, and idebenone without effect. 4 Levodopa was evaluated for movement disorders without effect. 4 Two patients on a low valine diet and a vitamin cocktail showed motor skill improvements. 26 Three patients on a low valine diet showed improvements in awareness, muscle tone, spontaneous movement, and language. 31 Triheptanoin (C7 oil) has been used to treat various fatty acid oxidation disorders [32] [33] [34] [35] and Glut-1 Deficiency Syndrome 33,36 with minimal to significant improvement in clinical symptoms. In most studies, triheptanoin replaced 30%-40% of daily calories 32, 36 in an otherwise normal diet. The C7 oil is well-tolerated; however, GI symptoms have been reported. 36 Triheptanoin replenishes the TCA cycle intermediates (known as anaplerosis), gluconeogenesis, and seems not to depend on SCEH for metabolism. Therefore, a trial of C7 oil appeared warranted in patients with SCEH deficiency.

Triheptanoin is a naturally occurring medium oddchain triglyceride which directly enters the mitochondria without the need for carnitine. 37 In the liver, C7 oil is metabolized to four carbon (acetoacetate and betahydroxybutyrate) and five carbon ketone bodies (Beta-hydroxypentanoate (BHP) and Beta-ketopentoate (BKP)) that are exported to peripheral tissues, including the brain, where they are converted to acetyl-CoA and propionyl-CoA. 32 Propionyl CoA is then converted to succinyl-CoA (by propionyl CoA carboxylase and methylmalonyl CoA mutase) before entering the TCA cycle directly (Figure 2 ). Propionyl-CoA also contributes to gluconeogenesis. Triheptanoin enters the mitochondria largely as the carboxylate, without the need for CPTI, carnitine-acylcarnitine translocase or CPTII. 37 It is then metabolized sequentially to acetyl CoA by medium chain-acyl-CoA synthetase, MCAD, IVCD, SCAD, and thiolase.

A female child with SCEH deficiency was treated with daily dosing of triheptanoin after approval of a single patient Investigational New Drug (IND) application. Ultragenyx Pharmaceuticals provided the triheptanoin which was administered enterally on an ascending dose regimen (5% to 40% of total daily calories divided into seven daily doses). Safety measures (blood and urine chemistries, EKG), neurological examination, physical examination, and motor function assessments were performed quarterly. Outcome measures included the following: (1) The Columbia Neurological Score (CNS), 38 

The patient, a 6 year 11 month old girl, presented at age 6 months with Leigh syndrome, global developmental delay, ptosis, oscillatory eye movements, mixed tone abnormalities, hyperreflexia, and bilateral Babinski signs. Compound heterozygous mutations in the ECHS1 gene (p. Ala173Val and p. Gly175Ser), confirmed the diagnosis of SCEH deficiency. Brain MRI at age 8 months showed mildly prominent CSF spaces, moderate overall symmetrical diminution in cerebral white matter volume, subtle nonspecific symmetric restricted diffusion, and T2 Figure 2 . Triheptanoin enters the mitochondria as a C7 fatty acid, each of which is metabolized to two C2 Acetyl CoA's, which directly enter the TCA cycle, and one C3 Propionyl CoA that is converted to methylmalonyl-CoA and then to succinyl-CoA, a TCA intermediate. At age 47 months, treatment with triheptanoin was initiated and has continued through age 6 years and 11 months. C7 oil was administered orally as an ascending dose (5% to 40% of total daily calories divided into 7 daily doses). The patient's condition has remained stable clinically since starting the C7 oil with subtle improvements in awareness, posture, purposeful movements, affect, and sleep pattern. (Table 1) . Urine organic acids levels varied. Lipid and hepatic profiles, basic metabolic panel, and complete blood count values were normal throughout. There has been no evidence of clinical regression or serious side effects over the 37 months of treatment. In-person evaluations were interrupted after 27 months due to COVID-19 restrictions.

We present a child with severe, early onset SCEH Deficiency treated successfully with triheptanoin. The patient presented early in infancy with clinical signs and laboratory findings typical of SCEH deficiency including severe developmental delay, abnormal brain MRI, elevation of urinary 3-methylglutaconic acid, and bi-allelic mutations in the ECHS1 gene. As expected, treatment with C7 oil resulted in increased medium and short chain acylcarnitine levels and elevations of urinary ketones. Baseline motor performance was severely delayed but stabilized after starting triheptanoin, followed by mild improvements in motor performance, head control, and sitting tolerance during the first 12 months. Motor skills continued to improve thereafter. Of note, there has been no clinical worsening which is commonly seen in untreated infantile onset disease. We were concerned when starting Triheptanoin as to whether SCEH is important in the metabolism of this heptanoate or any of its metabolites. The clinical improvement and the lack of any toxicity suggests that SCEH is not necessary or critical in the metabolism of these metabolites. Lifespan, at this point, has exceeded that of most early onset patients with SCEH deficiency. We have attributed the improvements in overall energy level, to C7 oil which replenishes TCA cycle intermediates, supports gluconeogenesis, and replaces fats commonly found in a standard diet. Daily total calories were maintained on a strict regimen accommodating standard protein and carbohydrate recommendations, and triheptanoin accounted for 40% of total daily calories. Limited protein intake accounted for reductions in dietary valine, but it is unclear whether decreased valine intake was therapeutic. Since most patients have the early onset severe phenotype, initiating treatment in the newborn period would seem to be ideal. Newborn screening would facilitate the diagnosis of genetically affected infants before or soon after onset of clinical symptoms permitting early treatment and protection of the developing nervous system. One of the limitations of this study is small sample size and delayed treatment. Continued evaluation of triheptanoin as a promising effective treatment for SCEH Deficiency is an important next step. 

ECHS1 mutations cause combined respiratory chain deficiency resulting in Leigh syndrome

ECHS1 mutations in Leigh disease: a new inborn error of metabolism affecting valine metabolism

Dystonia-ataxia syndrome with permanent torsional nystagmus caused by ECHS1 deficiency

Paroxysmal and non-paroxysmal dystonia in 3 patients with biallelic ECHS1 variants: expanding the neurological spectrum and therapeutic approaches

Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency

ECHS1 deficiency-associated paroxysmal exercise-induced dyskinesias: case presentation and initial benefit of intervention

Extrapolation of variant phase in mitochondrial shortchain Enoyl-CoA Hydratase (ECHS1) deficiency

ECHS1 deficiency as a cause of severe neonatal lactic acidosis

Wholeexome sequencing identifies novel ECHS1 mutations in Leigh syndrome

Clinical and biochemical characterization of four patients with mutations in ECHS1

Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement

Clinical, biochemical and metabolic characterisation of a mild form of human short-chain enoyl-CoA hydratase deficiency: significance of increased N-acetyl-S-(2-carboxypropyl)cysteine excretion

Novel ECHS1 mutation in an Emirati neonate with severe metabolic acidosis

Paroxysmal exercise-induced dystonia within the phenotypic spectrum of ECHS1 deficiency

A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders

Mitochondrial encephalopathy and transient 3-methylglutaconic aciduria in ECHS1 deficiency: long-term follow-up

Lethal neonatal case and review of primary short-chain enoyl-CoA hydratase (SCEH) deficiency associated with secondary lymphocyte pyruvate dehydrogenase complex (PDC) deficiency

A lethal neonatal phenotype of mitochondrial short-chain enoyl-CoA hydratase-1 deficiency

Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency

Clinical validity of biochemical and molecular analysis in diagnosing Leigh syndrome: a study of 106 Japanese patients

Clinical, biochemical, and genetic features of four patients with short-chain enoyl-CoA hydratase (ECHS1) deficiency

Next generation sequencing technologies for a successful diagnosis in a cold case of Leigh syndrome

An incidental finding in newborn screening leading to the diagnosis of a patient with ECHS1 mutations

Two novel ECHS1 variants, affecting splicing and reducing enzyme activity, is associated with mitochondrial encephalopathy in infant: a case report

Novel ECHS1 mutations in Leigh syndrome identified by whole-exome sequencing in five Chinese families: case report

Clinical, biochemical and metabolic characterization of patients with short-chain enoyl-CoA hydratase(ECHS1) deficiency: two case reports and the review of the literature

ECHS1 disease in two unrelated families of Samoan descent: common variant -rare disorder

Case report and novel treatment of an autosomal recessive Leigh syndrome caused by short-chain enoyl-CoA hydratase deficiency

A novel compound heterozygous variant of ECHS1 identified in a Japanese patient with Leigh syndrome

Mitochondrial fatty acid oxidation disorders associated with short-chain Enoyl-CoA Hydratase (ECHS1) deficiency

Medical nutrition therapy in patients with HIBCH and ECHS1 defects: clinical and biochemical response to low valine diet

Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride

Triheptanoin for the treatment of brain energy deficit: a 14-year experience

Clinical manifestations and management of fatty acid oxidation disorders

Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment-a retrospective chart review

Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement

Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential

Cerebral lactic acidosis correlates with neurological impairment in MELAS

The gross motor function measure: a means to evaluate the effects of physical therapy

Assessing functional differences in gross motor skills in children with cerebral palsy who use an ambulatory aid or orthoses: can the GMFM-88 help

The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability

The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of

We thank Ultragenyx Pharmaceuticals Inc. for providing triheptanoin for the purposes of this study. The Columbia University Institutional Review Board approved this study which was conducted under FDA IND #134770.

Melanie Brandabur is paid by Ultragenyx Pharmaceutical Inc.